ProPhase Labs (NASDAQ:PRPH) Rating Increased to Buy at StockNews.com

ProPhase Labs (NASDAQ:PRPHGet Rating) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a report issued on Thursday.

Separately, HC Wainwright raised their target price on ProPhase Labs from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Friday, November 11th.

ProPhase Labs Stock Up 2.1 %

Shares of NASDAQ:PRPH opened at $8.84 on Thursday. The firm has a market cap of $143.90 million, a P/E ratio of 4.86 and a beta of -0.26. The company has a quick ratio of 3.92, a current ratio of 4.21 and a debt-to-equity ratio of 0.12. ProPhase Labs has a 12-month low of $6.20 and a 12-month high of $15.25. The business has a fifty day simple moving average of $10.02 and a 200 day simple moving average of $10.99.

ProPhase Labs (NASDAQ:PRPHGet Rating) last announced its earnings results on Thursday, November 10th. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.09). The company had revenue of $24.20 million for the quarter, compared to the consensus estimate of $18.85 million. ProPhase Labs had a return on equity of 42.50% and a net margin of 21.58%. Analysts predict that ProPhase Labs will post 1.09 earnings per share for the current year.

Institutional Trading of ProPhase Labs

Large investors have recently bought and sold shares of the business. Bailard Inc. acquired a new stake in ProPhase Labs during the 3rd quarter worth about $126,000. Precision Wealth Strategies LLC acquired a new stake in ProPhase Labs during the 2nd quarter worth about $152,000. Goldman Sachs Group Inc. acquired a new stake in ProPhase Labs during the 2nd quarter worth about $164,000. Cambridge Investment Research Advisors Inc. acquired a new stake in ProPhase Labs during the 2nd quarter worth about $168,000. Finally, Cubist Systematic Strategies LLC grew its holdings in ProPhase Labs by 7.9% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 16,537 shares of the company’s stock worth $187,000 after acquiring an additional 1,205 shares during the period. 9.75% of the stock is currently owned by institutional investors and hedge funds.

ProPhase Labs Company Profile

(Get Rating)

ProPhase Labs, Inc is a medical science and technology company, which engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer healthcare products and dietary supplements. It operates through the Diagnostic Services and Consumer Products segment.

Recommended Stories

Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.